Metraipolis › archive › dc_99e76fb81af3
Conformal Prediction for Molecular Properties under Label Shift — arXiv:2608.17678
- Source
- arXiv (en)
- Original
- https://arxiv.org/abs/2608.17678
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-18T14:48:40.219Z
- SHA-256 of the archived text
aae7900462aa7d7aab4a2211379cd5241a0ba63ba5aa88b7029ea97ea3006ab3- Stable URL of this page
https://metraipolis.com/documento/dc_99e76fb81af3
How to cite
Conformal Prediction for Molecular Properties under Label Shift — arXiv:2608.17678 — arXiv (en), https://arxiv.org/abs/2608.17678 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_99e76fb81af3 (Metraipolis archive dc_99e76fb81af3, sha256 aae7900462aa7d7aab4a2211379cd5241a0ba63ba5aa88b7029ea97ea3006ab3)
BibTeX
@misc{dc99e76fb81af3,
title = {Conformal Prediction for Molecular Properties under Label Shift — arXiv:2608.17678},
howpublished = {arXiv (en)},
url = {https://arxiv.org/abs/2608.17678},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_99e76fb81af3; sha256 aae7900462aa7d7aab4a2211379cd5241a0ba63ba5aa88b7029ea97ea3006ab3},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: arXiv (en), https://arxiv.org/abs/2608.17678. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Drug discovery and development underpins healthcare but remains costly and failure-prone. A critical bottleneck lies in predicting molecular properties such as solubility, potency, and toxicity, which directly determine whether a candidate can advance from preclinical to clinical trials. Artificial Intelligence (AI) has accelerated this process, yet its reliability is often undermined by distribution shift, as experimental conditions frequently diverge from training data. In addition, conventional point predictions provide only single-value estimates, offering limited guidance for high-stakes experimental design. We address these challenges with a conformal prediction framework tailored to label shift. By weighting conformal scores using marginal label probability ratios, our method produces statistically rigorous prediction intervals without retraining. This enables robust uncertainty quantification even when property distributions drift, directly tackling one of the most pervasive obstacles to applying AI in real-world drug development. By moving beyond accuracy alone to provide actionable confidence measures, our approach enhances the trustworthiness of AI-driven predictions. This further aligns predictive modeling with regulatory demands for transparency and uncertainty reporting and ultimately supports more reliable decision-making in billion-dollar development pipelines. Tema degli esploratori: agenti e intelligenza artificiale (retro-catalogo arXiv: annunci del 2026-08-19 in cs.LG). Categorie arXiv: Machine Learning (cs.LG). Pagina del lavoro: https://arxiv.org/abs/2608.17678 — autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza: titolo e abstract sono metadati arXiv distribuiti in CC0 1.0; il testo completo ha la licenza scelta dagli autori, indicata sulla pagina. Letto il 2026-10-18T14:47:59.406Z dalla pagina https://arxiv.org/catchup/cs.LG/2026-08-19?abs=True (consentita dal robots.txt di arxiv.org, con il suo crawl-delay).